North America Conjugate Vaccine Market Size & Outlook
The conjugate vaccine market in North America is expected to reach a projected revenue of US$ 13,242.0 million by 2030. A compound annual growth rate of 9.2% is expected of North America conjugate vaccine market from 2024 to 2030.
Revenue, 2023 (US$M)
$7,161.7
Forecast, 2030 (US$M)
$13,242.0
CAGR, 2024 - 2030
9.2%
Report Coverage
North America
North America conjugate vaccine market, 2018-2030 (US$M)
North America conjugate vaccine market highlights
- The North America conjugate vaccine market generated a revenue of USD 7,161.7 million in 2023.
- The market is expected to grow at a CAGR of 9.2% from 2024 to 2030.
- In terms of segment, monovalent conjugate vaccine was the largest revenue generating product in 2023.
- Monovalent Conjugate Vaccine is the most lucrative product segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2023 | USD 7,161.7 million |
| Market revenue in 2030 | USD 13,242.0 million |
| Growth rate | 9.2% (CAGR from 2023 to 2030) |
| Largest segment | Monovalent conjugate vaccine |
| Fastest growing segment | Monovalent Conjugate Vaccine |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monovalent Conjugate Vaccine |
| Key market players worldwide | Bristol-Myers Squibb Co, Celgene, Eisai Co Ltd, Phaxiam, Roche Holding AG, Genmab A/S, GlaxoSmithKline, Novartis AG ADR, Pfizer Inc, Sanofi SA |
Other key industry trends
- In terms of revenue, North America region accounted for 37.7% of the global conjugate vaccine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,957.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Conjugate Vaccine Market Scope
Conjugate vaccine market segmentation & scope
Brand
Prevnar
Synflorix
PedvaxHIB
Hiberix
ACT-HIB
Pentacel
Menveo
Menactra
MenQuadfi
VAXNEUVANCE
CAPVAXIVE
Others
Disease
Pneumococcal
Influenza
DTP
Meningococcal
Typhoid
Pathogen
Bacterial
Viral
Combination
Patient
Pediatric
Adults
Countries
U.S.
Canada
Mexico
Japan
China
India
Australia
South Korea
Thailand
Brazil
Argentina
South Africa
Saudi Arabia
UAE
Kuwait
Conjugate Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America conjugate vaccine market
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
